Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEBNASDAQ:GNFTNASDAQ:IVANASDAQ:MDWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$1.08-4.4%$1.10$0.80▼$3.08$44.37M-1.1218,557 shs8,485 shsGNFTGenfit$4.31+0.5%$3.77$2.55▼$6.42$214.48M0.9214,656 shs4,791 shsIVAInventiva$3.30-1.9%$3.31$1.53▼$4.05$315.21M0.863,208 shs7,932 shsMDWDMediWound$21.08-1.1%$17.59$12.78▼$24.00$227.83M0.391,321 shs62,707 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+0.89%+11.87%-0.88%-8.13%-46.70%GNFTGenfit+1.28%-0.83%+17.69%+21.70%-5.43%IVAInventiva+8.32%+4.96%-12.98%+7.46%-2.45%MDWDMediWound+4.66%+2.16%+17.92%+33.42%+30.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANEBAnebulo Pharmaceuticals2.3458 of 5 stars3.53.00.00.03.31.70.0GNFTGenfit2.1219 of 5 stars3.55.00.00.02.10.00.0IVAInventiva2.2676 of 5 stars3.43.00.00.01.91.70.6MDWDMediWound1.8799 of 5 stars3.52.00.00.02.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 3.00Buy$5.50409.26% UpsideGNFTGenfit 3.00Buy$13.00201.62% UpsideIVAInventiva 2.80Moderate Buy$10.40215.63% UpsideMDWDMediWound 3.00Buy$31.2548.24% UpsideCurrent Analyst Ratings BreakdownLatest ANEB, MDWD, IVA, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025MDWDMediWoundHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.00 ➝ $31.005/15/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.005/2/2025MDWDMediWoundAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.004/4/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $9.003/28/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/20/2025MDWDMediWoundHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.002/28/2025MDWDMediWoundCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$39.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/AGNFTGenfit$67.00M3.22N/AN/A$1.48 per share2.91IVAInventiva$9.20M34.27N/AN/A($0.67) per share-4.92MDWDMediWound$19.21M11.86N/AN/A$3.43 per share6.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-119.54%-108.08%N/AGNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/AN/AIVAInventiva-$119.51MN/A0.00N/AN/AN/AN/AN/AN/AMDWDMediWound-$6.72M-$2.09N/AN/AN/A-142.29%-82.17%-33.67%8/13/2025 (Estimated)Latest ANEB, MDWD, IVA, and GNFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025MDWDMediWound-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 million5/13/2025Q3 2025ANEBAnebulo Pharmaceuticals-$0.05-$0.04+$0.01-$0.04N/AN/A3/19/2025Q4 2024MDWDMediWound-$0.59-$0.36+$0.23-$0.36$5.79 million$5.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A17.5117.51GNFTGenfit0.613.743.74IVAInventivaN/A0.590.59MDWDMediWoundN/A2.111.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%GNFTGenfit2.24%IVAInventiva19.06%MDWDMediWound46.83%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%GNFTGenfit4.20%IVAInventiva32.00%MDWDMediWound9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.09 million5.79 millionNot OptionableGNFTGenfit12050.00 million47.90 millionNot OptionableIVAInventiva10095.66 million35.68 millionNot OptionableMDWDMediWound8010.81 million9.79 millionOptionableANEB, MDWD, IVA, and GNFT HeadlinesRecent News About These CompaniesEquities Analysts Set Expectations for MediWound Q2 EarningsMay 27 at 1:25 AM | americanbankingnews.comWhat is HC Wainwright's Forecast for MediWound Q2 Earnings?May 27 at 1:18 AM | marketbeat.comNorthern Trust Corp Has $2.58 Million Holdings in MediWound Ltd. (NASDAQ:MDWD)May 26 at 3:12 AM | marketbeat.comMediWound (NASDAQ:MDWD) PT Set at $31.00 by HC WainwrightMay 25 at 1:51 AM | americanbankingnews.comHC Wainwright Forecasts Strong Price Appreciation for MediWound (NASDAQ:MDWD) StockMay 24, 2025 | marketbeat.comMediWound (NASDAQ:MDWD) Stock Crosses Above Fifty Day Moving Average - What's Next?May 24, 2025 | marketbeat.comMediWound (NASDAQ:MDWD) Releases Earnings Results, Beats Estimates By $0.58 EPSMay 23, 2025 | marketbeat.comMediWound’s Q1 2025: Strategic Progress Amid Financial ChallengesMay 22, 2025 | tipranks.comMediWound (MDWD) Q1 2025 Earnings Call TranscriptMay 21, 2025 | msn.comMediWound Ltd. (MDWD) Q1 2025 Earnings Call TranscriptMay 21, 2025 | seekingalpha.comMediWound (MDWD) Reports Q1 Loss, Misses Revenue EstimatesMay 21, 2025 | zacks.comMediWound Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 21, 2025 | globenewswire.comMediWound Q1 2025 Earnings PreviewMay 20, 2025 | msn.comMediWound Ltd.: Undervalued High-Growth PotentialMay 16, 2025 | seekingalpha.comMediWound (MDWD) to Release Earnings on WednesdayMay 16, 2025 | marketbeat.comMediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg UlcersMay 13, 2025 | globenewswire.comMediWound Ltd. (NASDAQ:MDWD) Shares Sold by Renaissance Technologies LLCMay 9, 2025 | marketbeat.comMediWound to Report First Quarter 2025 Financial ResultsMay 5, 2025 | globenewswire.comMediWound (NASDAQ:MDWD) Earns Buy Rating from Analysts at Alliance Global PartnersMay 4, 2025 | marketbeat.comMediWound to Present New EscharEx® Data at Leading Wound Care ConferencesApril 28, 2025 | globenewswire.comThose who invested in MediWound (NASDAQ:MDWD) five years ago are up 30%April 17, 2025 | finance.yahoo.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%Why Carnival Could Be the Ultimate Non-Tech Growth StockBy Jeffrey Neal Johnson | May 22, 2025View Why Carnival Could Be the Ultimate Non-Tech Growth StockCarnival's Comeback: Is the Stock Set for a Profitable Journey?By Jeffrey Neal Johnson | May 14, 2025View Carnival's Comeback: Is the Stock Set for a Profitable Journey?ANEB, MDWD, IVA, and GNFT Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$1.08 -0.05 (-4.42%) Closing price 03:50 PM EasternExtended Trading$1.08 +0.00 (+0.46%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Genfit NASDAQ:GNFT$4.29 +0.00 (+0.02%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Inventiva NASDAQ:IVA$3.30 -0.07 (-1.93%) Closing price 03:55 PM EasternExtended Trading$3.25 -0.04 (-1.37%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.MediWound NASDAQ:MDWD$21.08 -0.24 (-1.13%) Closing price 04:00 PM EasternExtended Trading$21.08 0.00 (-0.02%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
